Biointerfaces Institute welcomes new members of its External Advisory Board
The U-M Biointerfaces Institute welcomes Carl Gordon and Natasha Shervani of OrbiMed as new members of its External Advisory Board.
Department Chair Search
For information and to apply visit Faculty Search
The Biointerfaces Institute (BI) at the University of Michigan welcomes Carl Gordon and Natasha Shervani of OrbiMed as new members of its External Advisory Board (EAB). The EAB serves the institute by providing strategic insight, guidance, and assistance. EAB members are selected based upon demonstration of outstanding professional achievement, commitment to the long-term vitality of BI, and enhancement of the EAB’s breadth and diversity.
Created in 2012, the University of Michigan launched BI to accelerate the discoveries of new healthcare technologies. Through collaboration between life and physical sciences, institute researchers are advancing research in bio-innovations in brain cancer, nanotechnology, neural engineering, advanced materials and drug delivery, cell and tissue engineering, and single cell technologies.
“We hold the University of Michigan’s research enterprise in high regard and are excited to join the Biointerfaces Institute External Advisory Board to support the development of high-impact biomedical innovations,” said Carl Gordon, Managing Partner at OrbiMed Advisors.
Gordon has been a Managing Partner and Head of Global Private Equity at OrbiMed since 1998. He received his Bachelor of Fine Arts from Harvard College and PhD in Molecular Biology at Massachusetts Institute of Technology. He was a fellow at Rockefeller University from 1993 to 1995.
“We look forward to working with the world-class team at BI and supporting interdisciplinary research at the juncture of life sciences and physical sciences to develop real-world solutions that make a difference for patients,” added Natasha Shervani, investment professional at OrbiMed Advisors.
Shervani has been with OrbiMed since 2017. Previously, she was in the Investment Banking Division of Goldman Sachs in the Healthcare Group, where she worked on M&A and financing transactions for global life sciences, medical technology, and healthcare services clients. She graduated with honors from Brown University, receiving a Bachelor of Science in Materials Engineering and a Bachelor of Arts in South Asian Studies.
“I am very excited about having representation on BI’s External Advisory Board from one of the most premier venture capital firms. I am looking forward to working with Carl and Natasha and I am sure they will bring a unique perspective to BI and the University of Michigan”, says Joerg Lahann, the founding director of the Biointerfaces Institute.
By promoting continual collaboration between scientists, engineers and clinicians, BI is home to 30 research groups comprised of more than 300 students and researchers from the School of Dentistry, the College of Engineering, the School of Medicine, and the College of Pharmacy, collocated in over 56,000 square feet of dedicated, state-of-the-art facilities.